<DOC>
	<DOCNO>NCT01114438</DOCNO>
	<brief_summary>The purpose study evaluate EndoBarrier Gastrointestinal Liner post marketing environment subject obese Type 2 Diabetes .</brief_summary>
	<brief_title>Post Marketing Study Subjects Who Have Type 2 Diabetes Using EndoBarrier™ Gastrointestinal Liner</brief_title>
	<detailed_description>Patients obesity significantly great risk develop complication pulmonary dysfunction , diabetes , hypertension , co-morbid risk . NIH panel recommendation state even 10 % short-weight loss would greatly reduce risk . GI Dynamics ' EndoBarrier represent viable alternative short-term pre-surgical weight loss method . EndoBarrier device implant remove minimal invasive endoscopic technique . This endoscopic procedure bring potential benefit patient minimally invasive , efficacious , allow patient recover fast less morbidity mortality</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects Age &gt; 18 year ≤65 year Male Female Subjects Type 2 Diabetes &gt; 1 ≤ 10 year duration Subjects Hb A1c level &gt; 7.5 ≤ 10.0 Subjects take oral Type 2 Diabetes medication and/or insulin . Metformin allow , require . Subjects BMI &gt; 30 &lt; 50 Subjects willing comply study requirement Subjects sign informed consent form Women postmenopausal , surgically sterile contraceptive agree remain contraceptive duration study participation agree become pregnant study . Subjects take DPP4 inhibitor ( ie . Januvia ( sitagliptin ) , Galvus ( vildagliptin ) incretins ( ie . Byetta ( exenatide ) , Victoza ( liraglutide ) Subjects require insulin &gt; 150 unit per day • Subjects probable insulin production failure ( fast C Peptide serum &lt; 1.0 ng/mL ) Subjects diagnosed Type 1 Diabetes Mellitus history ketoacidosis Subjects require NSAIDs ( nonsteroidal antiinflammatory drug ) prescription anticoagulation therapy implant period Subjects history iron deficiency and/or iron deficiency anemia Subjects history abnormality GI tract Subjects symptomatic gallstone kidney stone time screening Subjects know infection Subjects history coagulopathy , upper gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasia Subjects mentally retard emotionally unstable , exhibit psychological characteristic , opinion Investigator , make subject poor candidate device placement clinical study participation Subjects previous GI surgery could affect ability place device function implant Subjects active H. pylorus ( Note : Subjects may enrol prior history H. Pylori successfully treat . If Subjects active H. pylorus baseline , receive appropriate treatment subsequently enroll study . ) Subject Family history know diagnosis preexist symptom systemic lupus erythematosus , scleroderma autoimmune connective tissue disorder Subjects active uncontrolled GERD Subjects severe liver kidney failure ( serum creatinine &gt; 180mmol/l ) Subjects poor dentition adequately chew food</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>